Introduction
Activating mutations in FLT3 (Fms-like tyrosine kinase) are among the most common genetic lesions in AML. Constitutive activation by acquired mutation occurs in approximately 30-35% of AML cases (reviewed in Parcells et al. ). The most common mutation is an internal tandem duplication (ITD) in the intracellular, juxtamembrane domain, which is present in approximately 20-25% of patients. In addition, approximately 7% of patients have point mutations in aspartic acid residue 835 in the tyrosine kinase domain (TKD). 1 Recent screens have also identified a range of other point mutations in FLT3 in AML. [2] [3] [4] FLT3-ITD and FLT3-TKD mutants induce distinct disease states in mouse models 5 and although FLT3-ITD mutations are associated with a poor prognosis, [6] [7] [8] [9] the prognostic implications of FLT3-TKD mutations are less clear. 9, 10 The signaling events induced by the activated FLT3 mutants presumably converge to modulate gene expression changes contributing to survival, proliferation and maintenance of differentiation arrest. Identification of the key downstream genes mediating these changes is an important step in understanding the basis of leukemic transformation. To date, few genes have been identified which lie in pathways downstream of the FLT3-ITD mutant. These include Pim2 and Id1 (upregulated), and Rgs2 (downregulated) which have been validated in functional studies. 11, 12 Downregulation of key growth arrest genes is an important downstream consequence of sustained growth factor receptor signaling 13 and these pathways may play a critical role in the growth promoting and leukemogenic properties of FLT3-activated mutants. The Growth Arrest and DNA DamageInducible (Gadd) 45a tumor suppressor gene is one of several genes shown to be downregulated by sustained receptor-mediated ERK1/2 activation. 13 It is a member of the Gadd gene family (Gadd45a, b and g) which encode small, acidic, nuclear proteins that interact with a number of cell cycle proteins linking DNA damage to cell cycle arrest and apoptosis. [14] [15] [16] [17] Gadd45a is directly activated by the tumor suppressors p53, C/EBPa and Egr-1 and is repressed by c-Myc. 18 Direct mutation or epigenetic modification of the Gadd45a locus has been reported in pancreatic and breast cancers. 19, 20 Loss of Gadd45a leads to genomic instability 21 and enhances development of multiple tumor types in susceptible mice. [22] [23] [24] [25] Here, we show that Gadd45a is a commonly downregulated target of leukemic receptor signaling. We show that Gadd45a mRNA is downregulated in a murine myeloid cell line model (FDB1) expressing the activated FLT3-ITD and FLT3-TKD receptor mutants, in FLT3-ITD þ AML cell lines and in FLT3-ITD þ AML. Here, we characterize the role of ERK1/2 activation in Gadd45a downregulation and the contribution of this downregulation to growth, viability and maintenance of the myeloid differentiation block.
Materials and methods

Gene set enrichment analysis: Wilcoxon's rank sum test
The 139 published Affymetrix probesets from the MU11K SubA Gene Chip used in the study by Mizuki et al. 11 were mapped to UniGene and Entrez Gene ID's using files obtained from the NetAffx website (http://www.affymetrix.com/). CompuGen Probe ID numbers used in the study by Brown et al. 26 were then mapped to NCBI Entrez Gene ID numbers using an inhouse developed Perl script, and to NCBI UniGene clusters (Build 139) using the SOURCE website (http://source.stanford. edu). Taking the distribution of FDR-adjusted P-values from the comparison of FDB1 cells expressing V449E versus wild-type receptor as the reference we used the Wilcoxon rank sum test to compare the distribution of FDR-adjusted P-values for all genes on the array with the FDR-adjusted P-values for the mapped probes from the genes identified by Mizuki et al.
11
Cell lines and treatment FDB1 cells were maintained as described earlier.
27 MV4;11 and MOLM-13 cells (obtained from DSMZ) were maintained in RPMI supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin.
Retroviral vectors and transduction
FLT3 receptor constructs are outlined in Supplementary Table 1 . Stable FDB1 cell populations expressing FLT3-WT, FLT3-ITD and FLT3-TKD were generated using a retroviral spinfection method. Briefly, retroviral supernatant was generated from HEK293T cells transfected with the pEQ ecotropic-packaging vector. 28 Cells and viral supernatant were centrifuged at 2000 r.p.m. for 1 h at 37 1C with 4 mg/ml polybrene. CD135 (FLT3) positive cells were sorted and cell lines were maintained in 1 mg/ml puromycin. The complete Gadd45a ORF was obtained from the EST Image Clone 4483665 (Invitrogen). Gadd45a was cloned into the retroviral vector, pRuf-IRESeGFP. 29 MV4;11 and MOLM-13 cells were transduced using the spinfection method as described above using amphotropic retrovirus. Transduced cells were sorted for GFP expression prior to assaying.
Cell cycle and annexin V analysis
For cell cycle analysis, cells were washed with PBS, and fixed overnight in 70% ethanol at À20 1C. Cells were spun and incubated in PBS, 0.1% Triton X-100, 100 mg/ml RNase A and 40 mg/ml propidium iodide (PI) for 30 min at 37 1C in the dark. Samples were analyzed with EXPO32 software on a BeckmanCoulter XL flow cytometer (Fullerton, CA, USA). For Annexin V (BD Biosciences, San Jose, CA, USA) staining, 100 000 cells were resuspended in 100 ml Binding Buffer and 5 ml Annexin V-PE. Cells were incubated for 15 min at room temperature in the dark before flow cytometric analysis.
Proliferation and differentiation assays
Growth was assessed using CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). To assess differentiation, cytospin preparations were made, and slides stained with May-Grü nwald Giemsa. In addition, cell surface staining was performed using a mouse Gr1-PE conjugate and isotype control, IgG2b-PE, from eBiosciences (San Diego, CA, USA) and analyzed by flow cytometry.
Quantitative RT-PCR
RNA was purified using the QIAGEN RNeasy Mini kit. Reverse transcription was performed using QIAGEN QuantiTect Reverse Transcription kit. RNA samples were treated with DNA-free (Ambion, Austin, TX, USA). Primers are available upon request. Gene-specific PCRs were performed as described earlier. 26 Expression of Gadd45a was determined relative to b-actin. All comparisons were performed across two independent experiments (n ¼ 2).
shRNA knockdown of Gadd45a
Gadd45a short-hairpin RNA (shRNA) retroviral constructs (pSM2c vector backbone) and non-silencing retroviral constructs were purchased from Open Biosystems (Huntsville, AL, USA) (Cat. no. RMM1766-96738882; RMM1766-96879424). Knockdown of Gadd45a mRNA was determined in each cell population using quantitative reverse transcription PCR (QRT-PCR).
Signaling analysis and inhibitors
Following pre-incubation with inhibitors for the indicated times, 3 Â 10 6 cells were washed in PBS and lysed in 100 ml modified RIPA Lysis Buffer. Proteins were separated on SDS-polyacrylamide gels and detected with phospho-specific antibodies as indicated. Total FLT3 and phospho-FLT3 were detected by western blotting using antibodies purchased from Cell Signaling Technology. Unless otherwise indicated the concentration of inhibitors were: 25 mM U0124 and U0126 (EMD Chemicals, San Diego, CA, USA), for FDB1 cells; 50 mM U0126 for MV4;11 cells; 2 mM GTP-14564 (EMD Chemicals). Table 2 .
AML panel and FLT3-ITD screening
Results
Identification of Gadd45a as a key target of leukemic receptor signaling
We have earlier described a number of activated mutants of the GM-CSF receptor (GMR) common b subunit 30 including a transmembrane mutant, GMR-V449E, which induces leukemia in a mouse bone marrow transplant model. 31 The effects of this mutant have been characterized extensively in the murine factor-dependent bi-potential myeloid cell line FDB1. 27 This cell line is factor-dependent for survival and switches between continuous proliferation in IL-3, and granulocyte-macrophage differentiation over 5 days in GM-CSF making it a useful model for studying the molecular events associated with proliferation and differentiation. 32 Expression of the GMR-V449E mutant in this cell line results in factor-independent growth and survival and is associated with a specific gene expression signature. 26 With a view to defining a gene expression pattern that is common to activated receptor signaling in leukemia, we compared the GMR-V449E-associated gene expression changes with those induced by the FLT3-ITD mutant found commonly in AML. The Wilcoxon rank sum test was used to measure the association between the GMR-V499E-regulated genes 26 and the 139 genes defined by Mizuki et al. 11 as differentially regulated in 32D cells expressing the FLT3-ITD mutant, when compared with wild-type FLT3 receptor. Our analysis revealed significant enrichment (P ¼ 2.8 Â 10 À7 ) of the genes associated with FLT3-ITD expression in the GMR-V449E gene set and highlighted specific genes displaying concordant regulation in response to these two receptor mutants (Table 1 ). For example, two genes earlier reported as downstream targets of FLT3-ITD (Pim2 and Rgs2 11,12 ) were concordantly regulated in these two studies. Further to this we have also examined the overlap with a gene set defined in a recent study that identified downstream targets of FLT3-ITD signaling 33 (Supplementary Figure 1) . Importantly, Gadd45a displayed significant, concordant downregulation in all three systems. Given the tumor suppressor properties of Gadd45a, we focused on the role of Gadd45a downregulation in AML.
Activated FLT3 mutants induce proliferation and block differentiation in FDB1 cells
We first generated model cell lines in which to investigate the role of Gadd45a downregulation downstream of activated FLT3 mutants. For this we introduced retroviral expression constructs of FLT3-WT, FLT3-ITD and FLT3-TKD into FDB1 cells. Receptor expression was confirmed in the derived cell populations by flow cytometry (Figure 1a) . Expression of the FLT3-ITD and FLT3-TKD mutants resulted in cell populations that were larger and more granular than the parental FDB1 cells or those expressing FLT3-WT, these features are consistent with a more mature myeloid intermediate (Figures 1a and b) . Importantly, expression of either FLT3-ITD or FLT3-TKD maintained a block in differentiation in the FDB1 cell populations in the absence of growth factor and in the presence of mGM-CSF (Figure 1b) , and supported continuous factor-independent proliferation ( Figure 1c ). The expression of the FLT3 mutants therefore induced a similar response to that of the GMR-V449E mutant. 31, 34 As shown in Figure 1d , both FLT3 mutants induced constitutive tyrosine phosphorylation of FLT3 as reported in 32D cells 35 and Ba/F3 cells. 2 Consistent with previous reports 5, 36 we also observed higher auto-phosphorylation of the FLT3-TKD receptor when compared with FLT3-ITD.
Gadd45a is a downstream repressed target of activated FLT3 and GM-CSF receptors that is regulated by ERK1/2 activity
To confirm the Gadd45a downregulation observed through microarray analysis we used quantitative reverse transcription PCR (QRT-PCR) to measure expression of Gadd45a mRNA in the FDB1 cell populations expressing GMR-V449E, FLT3-ITD and FLT3-TKD receptors. Gadd45a mRNA was significantly downregulated in response to the three activated mutants in the absence of growth factor, in mIL-3, or in mGM-CSF ( Figure 2a ). Gadd45a was also significantly downregulated in parental FDB1 cells cultured in mIL-3 relative to those in mGM-CSF ( Figure 2a ). In addition, we observed Gadd45a upregulation (1.8 fold) in the human FLT3-ITD þ AML cell line, MV4;11, in response to FLT3 inhibition (GTP-14564) ( Figure 2b ) consistent with the observation that Gadd45a mRNA is increased in 32D cells expressing FLT3-ITD following treatment with the FLT3 inhibitor MLN518 33 (Supplementary Figure 1) . We did not observe Gadd45a downregulation in normal bone marrow progenitors or human cord blood CD34 þ cells, when GMR-V449E, FLT3-ITD or FLT3-TKD receptors were expressed (data not shown). This suggests that Gadd45a downregulation in response to sustained receptor signaling requires secondary events associated with transformation, consistent with in vivo studies where FLT3-ITD expression induces a myeloproliferative phenotype characterized by increased proliferation and survival, but without a block in differentiation. 5, 37 Given that Gadd45a is one of several growth arrest genes found to be downregulated with sustained activation of the ERK1/2 pathway 13 we assessed whether constitutive and Genes showing concordant regulation in the two studies are listed. We analyzed the data from the study by Mizuki et al. 11 who identified 139 genes which were significantly differentially regulated by 2 fold or more in 32D cells expressing the FLT3-ITD compared with FLT3-WT receptor. The GMR-V449E-specific gene set (unfiltered, Po0.05) is described in Brown et al. GMR-V449E and MV4;11 cells were treated with the MEK inhibitor, U0126, or control, U0124 and Gadd45a mRNA levels were measured at 6 or 24 h using QRT-PCR (Figures 2c-f) . Following MEK inhibitor treatment, all cell lines displayed a significant increase in Gadd45a expression implicating ERK1/2 as a common regulator of Gadd45a expression in myeloid leukemia.
GADD45A expression in AML GADD45A mRNA levels were measured in a panel of AML samples to determine the association with the FLT3-ITD mutation. We found that GADD45A expression levels were significantly lower in FLT3-ITD þ AML than in FLT3-ITD À AML (P ¼ 0.01; Figure 3a) , consistent with FLT3-ITD-induced downregulation of GADD45A in human AML. We also extracted GADD45A expression data for primary AML samples from a published microarray study. 38 GADD45A was found to be significantly downregulated, relative to normal controls, in a number of AML clusters defined by their gene expression signature (Figures 3b and c) . The observation that one of the clusters displaying significant down regulation (cluster C6; P ¼ 0.03) contained only patients with FLT3-ITD mutations is consistent with the observation from our patient cohort. Clusters 2 and 3 defined two other groups with a high frequency of FLT3-ITD þ AML (82 and 53% FLT3-ITD mutations, respectively), and although lower GADD45A expression was seen in these clusters, it did not reach significance. Downregulation in Cluster 16, characterized by a t(11q23) rearrangement (predominantly MLL-AF9), is potentially through a related mechanism as 11q23 events have been associated with increased FLT3 expression in several studies. 39, 40 The observation that the cluster characterized by the presence of t(8;21) translocations (Cluster 13) showed reduced GADD45A expression raises the possibility that there may be an overlap in the mechanisms of leukemogenesis between FLT3-ITD þ leukemias and those involving the AML-ETO fusion. This is consistent with a recent report showing that FLT3-ITD signaling affects the repressor function of AML1. 41 shRNA knockdown of Gadd45a increases growth and survival of FDB1 cells
The growth arrest and pro-apoptotic properties of Gadd45a and its repression by leukemic cytokine receptors suggested that its downregulation may contribute to the maintenance of leukemic cell growth and viability. To assess the effects of Gadd45a downregulation in the myeloid compartment we transduced FDB1 cells with two shRNA retroviral constructs targeting different regions of the Gadd45a mRNA. Both shRNA retroviruses resulted in stable knockdown of Gadd45a mRNA (42 and 60%) (Figure 4a) Figure 3 Downregulation of GADD45A expression in AML. (a) GADD45A expression in AML patients at diagnosis. The presence of FLT3-ITD and FLT3-TKD was determined using FLT3-specific primers (see Supplementary Table 2 ). Patient details are given in Supplementary Table 2 .
Horizontal bar denotes the median. Mean GADD45A expression (normalized to b-actin) is represented as a ratio relative to the expression of GADD45A in a population of cord blood CD34 þ cells that was included in all experiments. A mixed effects linear model was used to estimate the mean change in expression due to the presence of FLT3-ITD, treating effects due to experiment and duplication within experiment as random effects (P ¼ 0.01, t-test). (b) Expression of GADD45A mRNA in AML. We determined the average levels of GADD45A mRNA in each AML cluster identified by Valk et al. 38 Plot shows normalized expression of GADD45A in each AML cluster (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) and in the normal control (CD34 þ and normal bone marrow (NBM)) (*Po0.05, # Po0.001, t-test). (c) Cluster details including number of patients, most common abnormality and fold expression change. For GADD45A we fitted a linear model to compare the average expression in patients from each of the 16 clusters defined by Valk et al. 38 relative to the pooled normal control. Significance was assessed using a moderated t-test in conjunction with a False Discovery Rate (FDR) adjustment of P-values to correct for multiple testing.
Gadd45a repression in AML M Perugini et al affect growth or viability of cells in mIL-3 where viability is normally greater than 90% (data not shown). Importantly both cell populations transduced with the Gadd45a shRNAs displayed a significant increase in cell viability and growth when cells were switched to GM-CSF, which normally results in a drop in viability associated with granulocyte-macrophage differentiation (Figures 4b and c) . Gadd45a downregulation is therefore sufficient to alter growth and viability in a myeloid cell line model of granulocyte-macrophage differentiation.
Overexpression of Gadd45a induces growth, viability and differentiation changes in FDB1 cells responding to GMR-V449E and FLT3-ITD mutants
We next tested whether enforced expression of Gadd45a in FDB1 populations expressing activated FLT3 and GM-CSF receptors affects growth, survival and/or differentiation. FDB1 cells expressing FLT3-ITD, FLT3-TKD or GMR-V449E were transduced with pRuf-IRES-eGFP and pRuf-IRES-eGFP-Gadd45a retroviruses. We tracked the proportion of Gadd45a-expressing cells (GFP þ ) during subsequent culture without factor. We observed a selective loss of Gadd45a/GFP þ cells (and concomitant appearance of GFP À cells) over a 7-day time course in the FLT3-ITD and GMR-V449E populations without factor, as well as in parental FDB1 populations in mIL-3 ( Figure 5a ). This is consistent with reduced growth and/or viability of the Gadd45a/GFP þ cells and subsequent selection for non-expressing cells. Interestingly, loss of Gadd45a/GFP þ cells was not observed in the FLT3-TKD cell population (Figure 5a ). Further examination of the selective growth of GFP cells in the respective populations confirmed that there was reduced expansion of the Gadd45a/GFP þ parental FDB1, GMR-V449E and FLT3-ITD populations relative to vector-only GFP þ cells ( Figure 5b) ; with no effect of Gadd45a overexpression on expansion of the FLT3-TKD cells. The reduced growth was also associated with a significant effect of Gadd45a overexpression on viability of parental FDB1 cells and cells expressing either GMR-V449E or the FLT3-ITD mutant, but was not apparent in the FLT3-TKD/FDB1 cells (Figure 5c ).
Gadd45a overexpression also had a striking affect on the differentiation status of the FDB1 cells expressing the GMR-V449E mutant. As reported earlier the expression of GMR-V449E in FDB1 cells leads to a marked downregulation of multiple differentiation-associated genes, including a number of C/EBPa targets. 26 The 'de-differentiation' activity of this mutant is apparent when the FDB1 cell populations are stained with Gr1, where we observe significantly lower Gr1 expression in the GMR-V449E cells relative to parental FDB1 cells maintained in mIL-3 (Figure 5d) . A reduced level of Gr1 expression is also seen in FLT3-ITD and FLT3-TKD populations (Figure 5d ) consistent with the overlap in signaling pathways and gene expression profiles. In the GMR-V449E cell population, forced expression of Gadd45a was sufficient to induce a significant increase in Gr1 levels (Figure 5d) , and increased C/EBPe mRNA expression (data not shown), in the Gadd45a/GFP þ cells. A similar increase was not observed in the FLT3-ITD GFP þ or FLT3-TKD GFP þ cell populations (Figure 5d ).
We also investigated the effects of forced Gadd45a expression in two human FLT3-ITD þ AML cell lines (MV4;11 and MOLM-13) using retroviral transduction to drive expression of Gadd45a. We found Gadd45a overexpression to be associated with increased Annexin V staining of GFP þ cells for both AML cell lines (Figures 6a and b) . In addition, overexpression of Gadd45a led to a dramatic reduction in growth rate (Figures 6c and d) . Consistent with this, both cell lines showed a loss in GFP þ cells over time which was more rapid for the faster cycling MOLM-13 cells than the MV4;11 cell line (Figures 6e and f) . Further to this, cell cycle analysis revealed that cells overexpressing Gadd45a became arrested primarily in G 0 /G 1 as determined by propidium iodide staining and flow cytometric analysis post-infection for MOLM-13 cells and MV4;11 cells (Figures 6g and h) . We did not observe changes associated with differentiation using a number of approaches, including surface marker expression and morphology assessment (data not shown). These results support the proposal that Gadd45a downregulation is critical for continuous growth and viability of AML cells.
Discussion
Identification of key downstream targets of FLT3 mutants is important for the development of more effective therapeutic approaches for AML. Here, we have identified a group of genes Figure 4 shRNA knockdown of Gadd45a in FDB1 cells. (a) FDB1 cells were transduced with retrovirus expressing a non-silencing shRNA or two independent Gadd45a shRNAs (Open Biosystems). Gadd45a mRNA levels were determined using QRT-PCR on RNA obtained from puromycin selected FDB1 cell populations maintained in GM-CSF for 5 days. Percentage knockdown is indicated. (b) Percentage viability was determined using trypan blue exclusion for FDB1 cell populations expressing Gadd45a shRNA constructs at day 3 and 5 in mGM-CSF (c). Equal numbers of each cell population were plated and total cell number was determined at each time point using trypan blue. Error bars represent the s.e. of the mean (n ¼ 3) (*Po0.01).
Gadd45a repression in AML
M Perugini et al commonly regulated in response to leukemic receptor signaling.
In particular we show that expression of the tumor suppressor gene Gadd45a, is downregulated in response to activated FLT3 mutants (FLT3-ITD and FLT3-TKD), and a leukemogenic trans-membrane mutant (GMR-V449E) of the GM-CSF receptor b-subunit. 31, 32 Sustained activation of ERK1/2 is associated with repression of a cohort of growth arrest genes, including
Gadd45a
13 and we observed increased Gadd45a mRNA following MEK inhibition in the FDB1 cells expressing these mutants and in the MV4:11 AML cell line. There are a number of possible mechanisms associated with sustained ERK1/2 signaling that may result in Gadd45a downregulation. One possible mechanism for Gadd45a downregulation may be through stabilization of c-Fos and enhanced AP-1 binding. 42 However, 
Gadd45a repression in AML M Perugini et al
ChIP analysis suggests that AP-1 does not bind directly to the Gadd45a promoter 13 and on this basis it has been proposed that Gadd45a downregulation may be mediated through a repressor which is an AP-1 target. It is also possible that ERK1/2 signaling regulates Gadd45a through inhibition of FoxO3a activity, 43 which normally activates Gadd45a expression, 44 or alternatively through inhibitory serine phosphorylation of C/EBPa which is known to regulate Gadd45a expression. 45 Our functional studies in the myeloid differentiation model, FDB1, using shRNA knockdown provide direct evidence that Gadd45a downregulation is associated with increased growth and survival under differentiation-promoting conditions. The predominant effects of overexpression of Gadd45a were observed in cells expressing the FLT3-ITD or GMR-V449E mutants and were on cell growth and survival, consistent with the growth arrest and pro-apoptotic activities of Gadd45a. 15, 46, 47 Cell cycle analysis of FDB1 cells and AML cell lines (MOLM-13 and MV4;11) overexpressing Gadd45a shows that arrest occurs at G1/S. The Gadd proteins interact directly with a number of cell cycle proteins including PCNA, p21 and cdc2/ CyclinB1 linking DNA damage to cell cycle arrest (reviewed in Hoffman and Liebermann 16, 17 ). All Gadd family members have been shown to induce G2/M cell cycle arrest by various mechanisms (reviewed in Hoffman and Liebermann 16, 17 ) and mounting evidence has also implicated Gadd family members in G1/S arrest. 17, 48, 49 Co-operation and direct interaction of Gadd45a with p21 may be critical for inducing arrest in G1/S phase of the cell cycle. 17 We also observed reduced survival when Gadd45a was overexpressed in the FDB1 cells expressing FLT3-ITD and GMR-V449E, and in the MV4;11 and MOLM-13 cells, consistent with a recognized role of Gadd45a in induction of apoptosis. 16, 17 Interestingly, we observed differences in susceptibility of the activated FLT3 and GM-CSF receptor mutants to Gadd45a overexpression. Only cells expressing FLT3-ITD or GMR-V449E showed reduced viability and growth. Cells expressing the FLT3-TKD mutant displayed a relative resistance to forced Gadd45a expression in the FDB1 system, with no effect on growth or viability. Although all receptor mutants (including FLT3-TKD) constitutively activate the ERK pathway, explaining transcriptional downregulation of Gadd45a, we and others have observed selective activation of STAT3 by FLT3-TKD (data not shown 2 ). This raises the possibility that STAT3 activation by FLT3-TKD may protect against the proapoptotic and growth arrest properties of Gadd45a overexpression. Alternatively, FLT3-TKD may provide an alternative, constitutive survival and/or proliferation pathway, or mediate post-translational modification and inactivation of Gadd45a.
A role for Gadd45a downregulation in suppression of differentiation was revealed in FDB1 cells expressing GMR-V449E where overexpression of Gadd45a was sufficient to induce changes associated with granulocyte differentiation. The ability of Gadd45a overexpression to selectively induce differentiation of the GMR-V449E cells may relate to the observation that this mutant appears to activate a limited complement of signaling events, predominantly ERK1/2 and JAK2-STAT5 pathways (unpublished data). Thus, although downregulation of Gadd45a appears to be necessary and sufficient for maintaining the differentiation block in the GMR-V449E cells, other events are likely to contribute to the differentiation block in the FLT3-ITD cells. For example, two other genes in the ERK1/2-repressed cohort described by Yamamoto et al., 13 the Mllt3 gene (myeloid/lymphoid or mixed lineage-leukemia translocation to 3 homolog) and Sox6, have been reported to be downregulated selectively by the FLT3-ITD mutant. 11 A role for Gadd45a in promoting granulocytic differentiation has also been suggested from gene ablation studies in mice; where complete loss of Gadd45a results in reduced numbers of granulocytes and increased blasts after GM-CSF treatment 50 consistent with a role in myeloid differentiation. This is also associated with an increased replating ability of CFU-GM from Gadd45aÀ/À bone marrow, suggesting a potential role for Gadd45a as an AML tumor suppressor gene. 50 Taken together with reports that Gadd45a is a target of C/ EBPa, 51, 52 Gadd45a may have an important role in promoting granulocyte differentiation. Gadd45a is also a direct target of C/EBPa in adipocytes 34, 35 and thus may have a more general role in coupling growth arrest to induction of differentiation.
Finally with regard to AML, our analysis of diagnostic patient samples and mining of AML gene expression profiling studies indicate that reduced GADD45A expression is associated with the presence of the FLT3-ITD mutation in AML samples. It is important now to define clearly the role of the ERK1/2 pathway in Gadd45a downregulation in AML as GADD45A represents a potentially important target for therapeutic reactivation, particularly in FLT3-ITD þ AML.
